BR0015788A - Agentes anti-diabéticos - Google Patents
Agentes anti-diabéticosInfo
- Publication number
- BR0015788A BR0015788A BR0015788-0A BR0015788A BR0015788A BR 0015788 A BR0015788 A BR 0015788A BR 0015788 A BR0015788 A BR 0015788A BR 0015788 A BR0015788 A BR 0015788A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- cow
- phenyl
- groups
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"AGENTES ANTI-DIABéTICOS". Compostos que são derivados de 1-( 2'-aminoacil )-2-cianopirrolidina de acordo com a fórmula geral ( 1 ) são inibidores da DP-IV para o tratamento da tolerância prejudicada à glicose ou do diabetes do tipo 2; nos quais A é selecionado a partir de grupos ( 2,3 e 4) X é selecionado a partir de grupos amino acila que correspondem aos aminoácidos naturais, grupos acila R^ 3^CO, grupos R^ 4^COOC( R^ 5^ )( R^ 6^ )OCO metoxicarbonila, etoxicarbonila e benziloxicarbonila; R^ 1^ é selecionado a partir de H, um resíduo de C~ 1~-C~ 6~ alquila, ( CH~ 2~ )~ a~ NH^ 1^, ( CH~ 2~ )~ b~COW^ 2^ (CH~ 2~)~ c~OW^ 3^, CH(Me)OW^ 4^ (CH~ 2~)~ d~-C~ 6 ~H~ 4~W^ 5^ , e ( CH~ 2~ )~ e~SW^ 6^, em que a é de 2 a 5,b é de 1 a 4, c é de 1 a 2, d é de 1 a 2, e é de 1 a 3, W^ 1^ é COW^ 6^ COW^ 6^ OU SO~ 2~W^ 6^, W^ 2^ é OH, NH~ 2~, OW^ 6^ ou NHW^ 6^ W^ 3^ é H OU W^ 6^ W^ 4^ é H OU W^ 6^ W^ 5^ é H, OH ou Ome, e W^ 6^ é C~ 1~ - C~ 6~ alquila, fenila opcionalmente substituída, heteroarila opcionalmente substituída ou benzila e R^ 2^ é selecionado a partir de H e (CH~ 2~)~ n~-C~ 5~H~ 3~N-Y, em que n é de 2 a 4 e Y é H, F, CL, NO~ 2~ ou CN, ou R^ 1^ e R^ 2^ em conjunto são -(CH~ 2~)p onde p é 3 ou 4; R^ 3^ é selecionado a partir de H, C~ 1~ C~ 6~ alquila e fenila; R^ 4^ é selecionado a partir de H, C~ 1~ - C~ 6~ alquila, benzila e fenila substituída de modo opcional; R^ 5^ e R^ 6^ são cada um de forma independente selecionados a partir de H e C~ 1~ - C~ 6~ alquila ou em conjunto são -(CH~ 2~)~ m~- onde m é de 4 a 6; R^ 7^ é selecionado a partir de piridila e fenila substituída de modo opcional; R^ 8^ é selecionado a partir de H e C~ 1~ - C~ 3~ alquila; e R^ 9^ é selecionado a partir de H, C~ 1~ - C~ 6~ alquila, C~ 1~ - C~ 6~ alcóxi e fenila.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9928330.1A GB9928330D0 (en) | 1999-11-30 | 1999-11-30 | Novel antidiabetic agents |
| PCT/GB2000/004572 WO2001040180A2 (en) | 1999-11-30 | 2000-11-30 | N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0015788A true BR0015788A (pt) | 2002-07-16 |
Family
ID=10865461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0015788-0A BR0015788A (pt) | 1999-11-30 | 2000-11-30 | Agentes anti-diabéticos |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US6911467B2 (pt) |
| EP (1) | EP1351932A2 (pt) |
| JP (1) | JP2003515585A (pt) |
| KR (1) | KR20020063185A (pt) |
| CN (1) | CN1192020C (pt) |
| AU (1) | AU781060B2 (pt) |
| BR (1) | BR0015788A (pt) |
| CA (1) | CA2392713A1 (pt) |
| CZ (1) | CZ20021520A3 (pt) |
| EE (1) | EE200200273A (pt) |
| GB (1) | GB9928330D0 (pt) |
| HR (1) | HRP20020421B1 (pt) |
| HU (1) | HUP0203700A3 (pt) |
| IL (2) | IL149359A0 (pt) |
| MX (1) | MXPA02005253A (pt) |
| MY (1) | MY131036A (pt) |
| NO (1) | NO20022502D0 (pt) |
| PL (1) | PL355333A1 (pt) |
| RU (1) | RU2265012C2 (pt) |
| SK (1) | SK7212002A3 (pt) |
| UA (1) | UA75341C2 (pt) |
| WO (1) | WO2001040180A2 (pt) |
| ZA (1) | ZA200204283B (pt) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| EP1406872B1 (en) * | 2001-06-20 | 2007-12-19 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| JP4300108B2 (ja) | 2001-06-27 | 2009-07-22 | スミスクライン ビーチャム コーポレーション | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
| NZ529973A (en) | 2001-06-27 | 2006-01-27 | Smithkline Beecham Corp | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| DE10154689A1 (de) * | 2001-11-09 | 2003-05-22 | Probiodrug Ag | Substituierte Aminoketonverbindungen |
| EP1399433B1 (en) | 2001-06-27 | 2007-08-22 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| GB0125446D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| CN1308311C (zh) | 2002-02-13 | 2007-04-04 | 霍夫曼-拉罗奇有限公司 | 新型吡啶－和喹啉－衍生物 |
| CA2474578C (en) | 2002-02-13 | 2009-08-25 | F. Hoffmann-La Roche Ag | Novel pyridin- and pyrimidin-derivatives |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| JP2006510630A (ja) * | 2002-12-04 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体 |
| CN1894234A (zh) * | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| DE602004026712D1 (de) | 2003-05-05 | 2010-06-02 | Probiodrug Ag | Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen |
| ATE464889T1 (de) | 2003-05-05 | 2010-05-15 | Probiodrug Ag | Medizinische verwendung von hemmern von glutaminyl und glutamatcyclasen |
| JP4806628B2 (ja) | 2003-05-05 | 2011-11-02 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤 |
| BRPI0411713B8 (pt) | 2003-06-20 | 2021-05-25 | Hoffmann La Roche | compostos, processo para a sua manufatura, composições farmacêuticas que compreendem os mesmos, método para tratamento e/ou profilaxia de enfermidades que estão associadas com dpp-iv e sua utilização |
| KR100744893B1 (ko) | 2003-06-20 | 2007-08-01 | 에프. 호프만-라 로슈 아게 | Ｄｐｐ-ｉｖ 저해제로서 헥사하이드로피리도아이소퀴놀린 |
| US7723344B2 (en) * | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7205409B2 (en) | 2003-09-04 | 2007-04-17 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| US20050065144A1 (en) * | 2003-09-08 | 2005-03-24 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| EP1699777B1 (en) * | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| MXPA06003998A (es) | 2003-10-15 | 2006-06-27 | Probiodrug Ag | Uso de efectores de ciclasas de glutamato y glutaminil. |
| US20050137142A1 (en) | 2003-11-03 | 2005-06-23 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| WO2005049022A2 (en) | 2003-11-17 | 2005-06-02 | Novartis Ag | Use of dipeptidyl peptidase iv inhibitors |
| SI3366283T1 (sl) | 2004-01-20 | 2021-12-31 | Novartis Ag | Formulacija za neposredno stiskanje in postopek |
| AU2005210004B2 (en) | 2004-02-05 | 2010-10-28 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102134230B (zh) * | 2004-03-15 | 2019-06-28 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| US7687638B2 (en) * | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| ATE553077T1 (de) | 2004-07-23 | 2012-04-15 | Nuada Llc | Peptidaseinhibitoren |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| KR100904829B1 (ko) | 2004-12-20 | 2009-06-25 | 에프. 호프만-라 로슈 아게 | 4-아미노피페리딘 유도체 |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| EP1828192B1 (en) | 2004-12-21 | 2014-12-03 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| TW200635930A (en) | 2004-12-24 | 2006-10-16 | Dainippon Sumitomo Pharma Co | Bicyclic pyrrole derivatives |
| WO2006116157A2 (en) | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-iv inhibitors |
| WO2006125227A2 (en) | 2005-05-19 | 2006-11-23 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| EP1910317B1 (en) | 2005-07-20 | 2013-07-03 | Eli Lilly And Company | 1-amino linked compounds |
| BRPI0614732A2 (pt) * | 2005-08-11 | 2011-04-12 | Hoffmann La Roche | composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados |
| EP1760076A1 (en) * | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
| CN102935081B (zh) * | 2005-09-14 | 2015-03-04 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
| SI1942898T2 (sl) | 2005-09-14 | 2014-08-29 | Takeda Pharmaceutical Company Limited | Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa |
| TW200745079A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor |
| CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
| TW200745080A (en) * | 2005-09-16 | 2007-12-16 | Takeda Pharmaceuticals Co | Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor |
| GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| US20100029941A1 (en) * | 2006-03-28 | 2010-02-04 | Takeda Pharmaceutical Company Limited | Preparation of (r)-3-aminopiperidine dihydrochloride |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2007123686A2 (en) * | 2006-03-31 | 2007-11-01 | Point Therapeutics, Inc. | Dpp inhibitors and uses thereof |
| BRPI0709984A2 (pt) | 2006-04-12 | 2011-08-02 | Probiodrug Ag | inibidores de enzima |
| JP5323684B2 (ja) | 2006-05-04 | 2013-10-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 多形体 |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| PT2073810E (pt) * | 2006-09-13 | 2011-09-30 | Takeda Pharmaceutical | Utilização de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo- 3,4-di-hidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo para tratamento de diabetes, cancro, distúrbios auto-imunes e infecção por vih |
| EP2089383B1 (en) | 2006-11-09 | 2015-09-16 | Probiodrug AG | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| TW200838536A (en) * | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US9126987B2 (en) | 2006-11-30 | 2015-09-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| KR20120030570A (ko) | 2007-04-03 | 2012-03-28 | 미쓰비시 타나베 파마 코퍼레이션 | 디펩티딜 펩티다아제 4 저해 화합물과 감미료와의 병용 |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2009037719A1 (en) * | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| ES2515194T3 (es) * | 2008-03-05 | 2014-10-29 | National Health Research Institutes | Derivados de pirrolidina |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| DE102008062136B4 (de) | 2008-12-16 | 2012-05-03 | Kamamed Ug | Pharmazeutische Zusammensetzung auf Basis von Peptid aus Kamelmilch |
| CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| GB2483614B (en) | 2009-06-18 | 2014-12-03 | Lupin Ltd | 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| NZ603319A (en) | 2010-06-24 | 2015-04-24 | Boehringer Ingelheim Int | Diabetes therapy |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| EP2686313B1 (en) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazole derivatives as inhibitors of glutaminyl cyclase |
| PL2731947T3 (pl) | 2011-07-15 | 2019-07-31 | Boehringer Ingelheim International Gmbh | Podstawiona dimeryczna pochodna chinazoliny, sposób jej wytwarzania i jej zastosowanie w kompozycjach farmaceutycznych do leczenia cukrzycy typu I i II |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| ES2950384T3 (es) | 2014-02-28 | 2023-10-09 | Boehringer Ingelheim Int | Uso médico de un inhibidor de DPP-4 |
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
| BR112019020485A2 (pt) | 2017-04-03 | 2020-05-12 | Coherus Biosciences, Inc. | Agonista ppary para tratamento de paralisia supranuclear progressiva |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN115368344A (zh) * | 2022-08-22 | 2022-11-22 | 湖北科技学院 | 组氨酸类衍生物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) * | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6319902B1 (en) * | 1997-08-22 | 2001-11-20 | Shionogi & Co., Ltd. | Peptide derivatives having thiazolyl-alanine residue |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| KR20010111277A (ko) | 1999-03-15 | 2001-12-17 | 추후제출 | 신규한 프로테아제 억제제 화합물 및 조성물 |
| GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
| GB9906715D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for promoting growth |
| US6172081B1 (en) | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
-
1999
- 1999-11-30 GB GBGB9928330.1A patent/GB9928330D0/en not_active Ceased
-
2000
- 2000-11-30 EP EP00977749A patent/EP1351932A2/en not_active Withdrawn
- 2000-11-30 HU HU0203700A patent/HUP0203700A3/hu unknown
- 2000-11-30 SK SK721-2002A patent/SK7212002A3/sk not_active Application Discontinuation
- 2000-11-30 UA UA2002054387A patent/UA75341C2/uk unknown
- 2000-11-30 IL IL14935900A patent/IL149359A0/xx active IP Right Grant
- 2000-11-30 JP JP2001541866A patent/JP2003515585A/ja active Pending
- 2000-11-30 BR BR0015788-0A patent/BR0015788A/pt not_active Application Discontinuation
- 2000-11-30 CN CNB008164568A patent/CN1192020C/zh not_active Expired - Fee Related
- 2000-11-30 CA CA002392713A patent/CA2392713A1/en not_active Abandoned
- 2000-11-30 KR KR1020027006133A patent/KR20020063185A/ko active IP Right Grant
- 2000-11-30 EE EEP200200273A patent/EE200200273A/xx unknown
- 2000-11-30 WO PCT/GB2000/004572 patent/WO2001040180A2/en not_active Application Discontinuation
- 2000-11-30 CZ CZ20021520A patent/CZ20021520A3/cs unknown
- 2000-11-30 RU RU2002117298/04A patent/RU2265012C2/ru not_active IP Right Cessation
- 2000-11-30 PL PL00355333A patent/PL355333A1/xx not_active Application Discontinuation
- 2000-11-30 MX MXPA02005253A patent/MXPA02005253A/es active IP Right Grant
- 2000-11-30 US US10/129,787 patent/US6911467B2/en not_active Expired - Fee Related
- 2000-11-30 AU AU15384/01A patent/AU781060B2/en not_active Ceased
-
2002
- 2002-04-25 IL IL149359A patent/IL149359A/en not_active IP Right Cessation
- 2002-05-14 MY MYPI20021737A patent/MY131036A/en unknown
- 2002-05-15 HR HR20020421A patent/HRP20020421B1/xx not_active IP Right Cessation
- 2002-05-27 NO NO20022502A patent/NO20022502D0/no not_active Application Discontinuation
- 2002-05-29 ZA ZA200204283A patent/ZA200204283B/xx unknown
-
2005
- 2005-04-15 US US11/106,594 patent/US7169806B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20020421B1 (en) | 2008-01-31 |
| EE200200273A (et) | 2003-06-16 |
| AU781060B2 (en) | 2005-05-05 |
| CA2392713A1 (en) | 2001-06-07 |
| CN1192020C (zh) | 2005-03-09 |
| US20030096857A1 (en) | 2003-05-22 |
| CN1402706A (zh) | 2003-03-12 |
| UA75341C2 (en) | 2006-04-17 |
| MY131036A (en) | 2007-07-31 |
| HUP0203700A3 (en) | 2004-01-28 |
| NO20022502L (no) | 2002-05-27 |
| WO2001040180A3 (en) | 2001-11-08 |
| HRP20020421A2 (en) | 2004-02-29 |
| US6911467B2 (en) | 2005-06-28 |
| AU1538401A (en) | 2001-06-12 |
| US20050203031A1 (en) | 2005-09-15 |
| NO20022502D0 (no) | 2002-05-27 |
| US7169806B2 (en) | 2007-01-30 |
| CZ20021520A3 (cs) | 2002-10-16 |
| SK7212002A3 (en) | 2002-12-03 |
| WO2001040180A2 (en) | 2001-06-07 |
| PL355333A1 (en) | 2004-04-19 |
| ZA200204283B (en) | 2003-09-03 |
| EP1351932A2 (en) | 2003-10-15 |
| GB9928330D0 (en) | 2000-01-26 |
| MXPA02005253A (es) | 2002-11-07 |
| RU2265012C2 (ru) | 2005-11-27 |
| KR20020063185A (ko) | 2002-08-01 |
| JP2003515585A (ja) | 2003-05-07 |
| IL149359A (en) | 2007-10-31 |
| HUP0203700A2 (hu) | 2003-03-28 |
| IL149359A0 (en) | 2002-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0015788A (pt) | Agentes anti-diabéticos | |
| DK1265606T3 (da) | Celleadhæsionsinhibitorer | |
| TR200200082T2 (tr) | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi. | |
| BRPI0111596B8 (pt) | Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto | |
| NO20021399L (no) | Kazolinderivater og deres anvendelse som farmasöyter | |
| NL350075I2 (pt) | ||
| TR200200205T2 (tr) | MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi | |
| BR9806752A (pt) | Ftalazinonas. | |
| RS49673B (sr) | Inhibitori sintaze azot-monoksida | |
| NZ516599A (en) | 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands | |
| CA2316310A1 (en) | Gamma-glutamyl and beta-aspartyl containing immunomodulator compounds and methods therewith | |
| DK0766696T3 (da) | Thiazolidinderivater, fremstilling af disse forbindelser og lægemidler indeholdende disse forbindelser | |
| DE60230127D1 (de) | Inhibitoren von integrin alpha-v-beta-6 | |
| NO974843L (no) | Benzimidazolforbindelser, farmasöytiske sammensetninger som inneholder forbindelsene og deres anvendelser | |
| BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
| DK1077218T3 (da) | Peptidomimetiske forbindelser omfattende RGD-sekvenser, som er nyttige som integrininhibitorer | |
| BRPI0418255A (pt) | derivados de piperazina e piperidina n-substituìdos | |
| BR9713207A (pt) | Derivados de 3-mercaptoacetilamino-1,5-substituìdo-2-oxo-azepan uteis como inibidores de metaloproteinase de matriz | |
| DE60202669D1 (de) | 6-phenylbenzonaphthyidine | |
| HUP9902465A1 (hu) | Új amidínium-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| NZ332597A (en) | Alkyloxyamino substituted fluoren-9-ones and their use as protein kinase c inhibitors | |
| BR0307016A (pt) | ácidos 3-(imidazolil)-2-alcoxipropanóicos | |
| IT1293777B1 (it) | Processo per la preparazione di tetraazamacrocicli | |
| EA200600608A1 (ru) | Производные имидазопиридина как ингибиторы индуцируемой no-синтазы | |
| DE60110233D1 (de) | Neue n-(2-phenyl-3-aminopropyl)naphtamide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] |
Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO. |
|
| B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
| B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |